We are live on ! Find out more
RGC icon

Regencell Bioscience
RGC

5 hedge funds and large institutions have $434K invested in Regencell Bioscience in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

150% more funds holding

Funds holding: 2 → 5 (+3)

89% more capital invested

Capital invested by funds: $230K → $434K (+$204K)

3.88% more ownership

Funds ownership: 2.05% → 5.93% (+3.9%)

Holders
5
Holders Change
+3
Holders Change %
+150%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
1
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$565K
2
Citigroup
Citigroup
New York
+$73K
3
TRCT
Tower Research Capital (TRC)
New York
+$14.1K
4
UBS Group
UBS Group
Switzerland
+$1.69K
5
Morgan Stanley
Morgan Stanley
New York
+$195

Top Sellers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
-$224K
Name Holding Trade Value Shares
Change 		Change in
Stake
Qube Research & Technologies (QRT)
1
Qube Research & Technologies (QRT)
United Kingdom
$371K +$565K +658,502 New
Citigroup
2
Citigroup
New York
$48K +$73K +85,120 New
TRCT
3
Tower Research Capital (TRC)
New York
$10K +$14.1K +16,416 New
UBS Group
4
UBS Group
Switzerland
$5K +$1.69K +1,976 +27%
Geode Capital Management
5
Geode Capital Management
Massachusetts
– -$224K -259,008 Closed
Morgan Stanley
6
Morgan Stanley
New York
– +$195 +228 New

RGC Hedge Fund Activity: Q1 2022 in Review

5 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Regencell Bioscience (RGC) for Q1 2022, worth a combined $434K — up 89% from $230K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new RGC positions and 1 closed out — a net gain of 3 holders — while 1 added to existing stakes and 0 trimmed.

The largest buyer was Qube Research & Technologies (QRT), opening a new position worth an estimated $565K. The largest seller was Geode Capital Management, exiting entirely with an estimated $224K sold.

  • 5 institutional investors held Regencell Bioscience (RGC) as of Q1 2022, up from 2 in Q4 2021.
  • Funds reported $434K of Regencell Bioscience stock for Q1 2022, up 89% quarter-over-quarter.
  • 4 funds opened new Regencell Bioscience positions in Q1 2022 and 1 closed out, a net change of +3 holders.
  • The largest Regencell Bioscience buyer in Q1 2022 was Qube Research & Technologies (QRT), an estimated $565K added.
  • The largest Regencell Bioscience seller in Q1 2022 was Geode Capital Management, an estimated $224K sold.

Based on aggregated 13F filings for Q1 2022.